308 related articles for article (PubMed ID: 30784894)
1. Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy.
Weingarten N; Kruser TJ; Bloch O
Clin Neurol Neurosurg; 2019 Apr; 179():14-18. PubMed ID: 30784894
[TBL] [Abstract][Full Text] [Related]
2. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
[TBL] [Abstract][Full Text] [Related]
3. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
Colaco RJ; Martin P; Kluger HM; Yu JB; Chiang VL
J Neurosurg; 2016 Jul; 125(1):17-23. PubMed ID: 26544782
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
5. Risk of symptomatic radiation necrosis in patients treated with stereotactic radiosurgery for brain metastases.
Sayan M; Şahin B; Mustafayev TZ; Kefelioğlu EŞS; Vergalasova I; Gupta A; Balmuk A; Güngör G; Ohri N; Weiner J; Karaarslan E; Özyar E; Atalar B
Neurocirugia (Astur : Engl Ed); 2021; 32(6):261-267. PubMed ID: 34743823
[TBL] [Abstract][Full Text] [Related]
6. Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study.
Lehrer EJ; Gurewitz J; Bernstein K; Patel D; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Malouff TD; Ruiz-Garcia H; Patel S; Bonney PA; Hwang L; Yu C; Zada G; Mathieu D; Trudel C; Prasad RN; Palmer JD; Jones BM; Sharma S; Fakhoury KR; Rusthoven CG; Deibert CP; Picozzi P; Franzini A; Attuati L; Lee CC; Yang HC; Ahluwalia MS; Sheehan JP; Trifiletti DM
Cancer; 2022 Apr; 128(7):1429-1438. PubMed ID: 35077586
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric Factors Related to Radiation Necrosis After 5-Fraction Radiosurgery for Patients With Resected Brain Metastases.
Tanenbaum DG; Buchwald ZS; Jhaveri J; Schreibmann E; Switchenko JM; Prabhu RS; Chowdhary M; Abugideiri M; Pfister NT; Eaton B; Kahn SE; Olson JJ; Shu HG; Crocker IR; Curran WJ; Patel KR
Pract Radiat Oncol; 2020; 10(1):36-43. PubMed ID: 31586666
[TBL] [Abstract][Full Text] [Related]
8. Incidence of radionecrosis in single-fraction radiosurgery compared with fractionated radiotherapy in the treatment of brain metastasis.
Donovan EK; Parpia S; Greenspoon JN
Curr Oncol; 2019 Jun; 26(3):e328-e333. PubMed ID: 31285676
[TBL] [Abstract][Full Text] [Related]
9. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
10. Risk of radiation necrosis after hypofractionated stereotactic radiotherapy (HFSRT) for brain metastases: a single center retrospective study.
Di Perri D; Tanguy R; Malet C; Robert A; Sunyach MP
J Neurooncol; 2020 Sep; 149(3):447-453. PubMed ID: 32979130
[TBL] [Abstract][Full Text] [Related]
11. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies.
Kim JM; Miller JA; Kotecha R; Xiao R; Juloori A; Ward MC; Ahluwalia MS; Mohammadi AM; Peereboom DM; Murphy ES; Suh JH; Barnett GH; Vogelbaum MA; Angelov L; Stevens GH; Chao ST
J Neurooncol; 2017 Jun; 133(2):357-368. PubMed ID: 28434110
[TBL] [Abstract][Full Text] [Related]
12. Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer: A Retrospective Review.
Sharma A; Mountjoy LJ; Butterfield RJ; Zhang N; Ross HJ; Schild SE; Sio TT; Daniels TB; Paripati HR; Mrugala MM; Vora SA; Patel NP; Zimmerman RS; Ashman JB; Porter AB
Am J Clin Oncol; 2020 Feb; 43(2):128-132. PubMed ID: 31764021
[TBL] [Abstract][Full Text] [Related]
13. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery.
Blonigen BJ; Steinmetz RD; Levin L; Lamba MA; Warnick RE; Breneman JC
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):996-1001. PubMed ID: 19783374
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
Kowalski ES; Remick JS; Sun K; Alexander GS; Khairnar R; Morse E; Cherng HR; Berg LJ; Poirier Y; Lamichhane N; Becker S; Chen S; Molitoris JK; Kwok Y; Regine WF; Mishra MV
Radiat Oncol; 2020 Oct; 15(1):245. PubMed ID: 33109224
[TBL] [Abstract][Full Text] [Related]
15. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
Patel KR; Chowdhary M; Switchenko JM; Kudchadkar R; Lawson DH; Cassidy RJ; Prabhu RS; Khan MK
Melanoma Res; 2016 Aug; 26(4):387-94. PubMed ID: 27223498
[TBL] [Abstract][Full Text] [Related]
16. Significance of target location relative to the depth from the brain surface and high-dose irradiated volume in the development of brain radionecrosis after micromultileaf collimator-based stereotactic radiosurgery for brain metastases.
Ohtakara K; Hayashi S; Nakayama N; Ohe N; Yano H; Iwama T; Hoshi H
J Neurooncol; 2012 May; 108(1):201-9. PubMed ID: 22392126
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery.
Boothe D; Young R; Yamada Y; Prager A; Chan T; Beal K
Neuro Oncol; 2013 Sep; 15(9):1257-63. PubMed ID: 23814264
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients.
Lehrer EJ; Khosla AA; Ozair A; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Mathieu D; Trudel C; Deibert CP; Malouff TD; Ruiz-Garcia H; Peterson JL; Patel S; Bonney P; Hwang L; Yu C; Zada G; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Fakhoury KR; Rusthoven CG; Dickstein DR; Sheehan JP; Trifiletti DM; Ahluwalia MS
J Neurooncol; 2023 Oct; 165(1):63-77. PubMed ID: 37889444
[TBL] [Abstract][Full Text] [Related]
19. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors.
Sneed PK; Mendez J; Vemer-van den Hoek JG; Seymour ZA; Ma L; Molinaro AM; Fogh SE; Nakamura JL; McDermott MW
J Neurosurg; 2015 Aug; 123(2):373-86. PubMed ID: 25978710
[TBL] [Abstract][Full Text] [Related]
20. Single-Fraction Stereotactic Radiosurgery (SRS) Alone Versus Surgical Resection and SRS for Large Brain Metastases: A Multi-institutional Analysis.
Prabhu RS; Press RH; Patel KR; Boselli DM; Symanowski JT; Lankford SP; McCammon RJ; Moeller BJ; Heinzerling JH; Fasola CE; Asher AL; Sumrall AL; Buchwald ZS; Curran WJ; Shu HG; Crocker I; Burri SH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):459-467. PubMed ID: 28871997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
